Inicio>>Signaling Pathways>> Proteases>> Lipoxygenase>>Malotilate

Malotilate (Synonyms: NKK-105)

Catalog No.GC14751

El malotilato (NKK 105), un agente hepatotrÓpico activo por vÍa oral y una sustancia antifibrÓtica, inhibe selectivamente la 5-lipoxigenasa (5-LOX) (IC50 = 4,7 μM). El malotilato previene el desarrollo de lesiÓn hepatocÍtica en la hepatitis por alcohol-pirazol al disminuir los niveles de acetaldehÍdo hepÁtico y prevenir la retenciÓn de transferrina en los hepatocitos.

Products are for research use only. Not for human use. We do not sell to patients.

Malotilate Chemical Structure

Cas No.: 59937-28-9

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
61,00 $
Disponible
5mg
36,00 $
Disponible
100mg
150,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IC50: N/A

Malotilate (diisopropyl-l,3-dithiol-2-ylidenemalonate) is a novel hepatotrophic drug, which can improve protein metabolism and stimulate hepatocyte regeneration.

In vitro: The in-vitro invasion assay employing a rat lung endothelial cell monolayer indicated that pretreatment of the lung endothelial cells, but not c-SST-2 cells, with malotilate reduced the invasion of the RLE monolayer by c-SST-2 cells significantly. The in-vitro vascular permeability assay also demonstrated malotilate could prevent the permeability increase of the lung endothelial cell monolayer by serum starvation. In contrast, the gelatinase production and adhesion to the RLE cell monolayer of c-SST-2 cells were not affected by malotilate treatment [1].

In vivo: Malotilate was administered to syngeneic SHR rats orally from 7 days before or after s.c. inoculation of c-SST-2 cells until the end of the experiments. In the malotilate-treated rats, pulmonary metastasis was suppressed markedly when compared with the non-treated rats. Moreover, in the rats treated with malotilate for 19 days after inoculation of c-SST-2 cells, lung metastasis was also suppressed significantly [1].

Clinical trial: A previous clinical trial results indicated that malotilate could accelerate the recovery of impaired protein metabolism in alcoholic liver disease and thus malotilate might be useful for the treatment of alcoholic liver diseases [2].

References:
[1] Nagayasu H,Hamada J,Kawano T,Konaka S,Nakata D,Shibata T,Arisue M,Hosokawa M,Takeichi N,Moriuchi T.  Inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells. Br J Cancer.1998 May;77(9):1371-7.
[2] Takase S,Matsuda Y,Yasuhara M,Takada A.  Effects of malotilate treatment on alcoholic liver disease. Alcohol.1989 May-Jun;6(3):219-22.

Reseñas

Review for Malotilate

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Malotilate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.